Detection of SARS-CoV-2 BA.2.86 by lateral flow devices.

Autor:	Bown A; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK. Electronic address: abbie.bown@ukhsa.gov.uk., Sweed A; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Catton M; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Nelthorpe-Cowne J; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Conti-Frith H; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Elderfield R; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Terrey J; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Abib H; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Lui C; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Fisher E; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Bewley KR; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Coombes NS; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Robinson D; Product and Delivery, UK Health Security Agency, UK., Agrawal S; Product and Delivery, UK Health Security Agency, UK., Hallis B; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Blandford E; Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK., Fowler T; Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK., Williamson DA; Specialist Microbiology and Laboratories, UK Health Security Agency, UK., Vipond R; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Feb; Vol. 139, pp. 168-170. Date of Electronic Publication: 2023 Dec 25.
DOI:	10.1016/j.ijid.2023.12.010
Abstrakt:	We evaluated the performance of 12 lateral flow devices by assessing their analytical sensitivity for SARS-CoV-2 variant BA.2.86. Kits from ACON, Orient Gene, Xiamen Biotime, Getein, and SureScreen detected variant BA.2.86 to sufficient sensitivity levels, comparable to those observed with previous Omicron variants. The stocks of lateral flow devices currently held by the UK government do not currently need changing for deployment for this variant. Competing Interests: Declarations of competing interest The authors have no competing interests to declare. (Copyright © 2023. Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu